The goal of this clinical trial is to compare the safety and efficacy of conscious sedation and general anesthesia in patients with paroxysmal atrial fibrillation undergoing their first pulsed-field ablation (PFA) procedure. It will also establish a scalable conscious sedation protocol for PFA. The main questions it aims to answer are: 1. Does conscious sedation reduce the incidence of the composite safety endpoint (persistent hypotension or hypoxemia for more than 60 seconds intraoperatively) compared with general anesthesia? 2. What are the differences in perioperative indicators and adverse events between the two anesthetic strategies in PFA for paroxysmal atrial fibrillation? Researchers will randomly assign eligible patients to a conscious sedation group or a general anesthesia group at a 1:1 ratio to compare the safety and efficacy of the two anesthetic approaches. Participants will: 1. Receive the assigned anesthetic strategy combined with standardized PFA procedure 2. Complete intraoperative vital sign and related index monitoring 3. Undergo follow-up visits at 12-24 hours, 30 days and 90 days after surgery for relevant index assessment and adverse event recording
Atrial fibrillation (AF) is the most prevalent cardiac arrhythmia, which severely impairs patients' quality of life and is closely associated with an elevated risk of complications including thromboembolism and heart failure. Rhythm control, particularly catheter ablation, has become a cornerstone of AF management. In recent years, pulsed-field ablation (PFA) has emerged as a novel catheter ablation technique for AF. It demonstrates non-inferior ablation efficacy to conventional radiofrequency ablation, with the advantages of minimal injury to peri-myocardial tissues, high procedural efficiency and a low incidence of complications, thus serving as a promising alternative for AF catheter ablation. Unlike radiofrequency ablation, PFA delivers high-voltage electric fields during the procedure, for which local anesthesia fails to achieve satisfactory sedation and analgesia. General anesthesia (GA) is currently the main anesthetic approach for PFA to ensure adequate intraoperative immobilization and provide stable conditions for precise procedural manipulation. However, GA has notable limitations: first, the central inhibitory effects of general anesthetics and procedural stress-induced responses are prone to cause perioperative hemodynamic instability, leading to adverse events such as hypotension and hypoxemia, which not only increase procedural risks but also exert adverse impacts on short- and long-term patient prognosis; second, GA usually requires endotracheal intubation or laryngeal mask ventilation, which may cause retropharyngeal injury and raise the risk of complications like bleeding or hematoma; third, GA incurs relatively high medical costs, further increasing the economic burden on patients. In light of these unmet clinical needs, several observational studies have demonstrated the feasibility of deep or conscious sedation during PFA procedures. Nevertheless, sedation strategies vary across centers, and most findings are based on single-center, small-sample empirical summaries, lacking high-quality evidence from large-sample, rigorously designed randomized controlled trials (RCTs). Our team has previously explored a conscious sedation strategy in over 200 patients, and the results showed that this strategy could achieve satisfactory sedation and analgesia for PFA, significantly reduce the risk of GA-related hemodynamic instability, and yield favorable postoperative feedback from patients. Given the sufficient evidence supporting the efficacy and safety of PFA in the treatment of paroxysmal atrial fibrillation (PAF), this study intends to conduct a single-center, 1:1 randomized, single-blind controlled trial to compare the safety and efficacy of conscious sedation and GA in PFA for PAF, aiming to provide an evidence-based basis for the selection of an optimal sedation regimen for PFA procedures.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
SINGLE
Enrollment
224
Medications: Remimazolam toluenesulfonate injection (25 mg) + Fentanyl citrate injection (0.1 mg) + Lidocaine (100 mg). Administration method: Remimazolam: 2 vials mixed with 50 mL of 0.9% sodium chloride injection to prepare a solution with a concentration of 1 mg/mL. The target Bispectral Index (BIS) is 60-80, and the infusion rate of remimazolam is adjusted according to the BIS and patient responses. Fentanyl citrate: 5 vials mixed with 50 mL of 0.9% sodium chloride injection to prepare a solution with a concentration of 0.01 mg/mL. Dose reduction and slower injection rate are required for patients with hepatic/renal insufficiency, obesity, or elderly/weak conditions.
After femoral vein puncture, anesthesia induction was performed with remimazolam (0.2-0.3 mg/kg), sufentanil (0.3-0.4 μg/kg) and rocuronium (0.6 mg/kg) following standard monitoring and preoxygenation. A laryngeal mask airway was inserted upon loss of consciousness and adequate muscle relaxation, with lung-protective mechanical ventilation applied at tidal volume 6-8 mL/kg, respiratory rate 10-14 breaths/min, I:E 1:2, FiO₂ 60% and fresh gas flow 2-3 L/min to maintain PaCO₂ at 35-45 cmH₂O. Anesthesia was maintained with continuous intravenous ciprofol (0.4-1 mg/kg/h) and remifentanil (0.1-0.2 μg/kg/min) to keep BIS 60-80 and MAP \>70 mmHg, with vasoactive agents as needed. Anesthetics were discontinued before surgery end; the laryngeal mask airway was removed after the patient regained consciousness with satisfactory spontaneous breathing, and antagonistic drugs were used if necessary.
Beijing Anzhen Hospital
Beijing, Beijing Municipality, China
Primary outcome
persistent systolic blood pressure \<85 mmHg for more than 60 seconds, or persistent hypoxemia (SpO₂ \<85%) for more than 60 seconds.
Time frame: During procedure
Individual components of the primary composite endpoint
persistent systolic blood pressure \<85 mmHg for more than 60 seconds, or persistent hypoxemia (SpO₂ \<85%) for more than 60 seconds.
Time frame: During procedure
The number of occurrences of each component of the primary outcome
The number of occurrences of each component of the primary outcome: (1) Systolic blood pressure persistently below 85 mmHg for more than 60 sec; or (2) Persistent hypoxemia (SpO₂ \< 85%) for more than 60 seconds.
Time frame: During procedure
Sedation difficulty score
1-10; 1 = easiest, 10 = most difficult
Time frame: During procedure
Total procedure time
from femoral vein puncture to sheath removal
Time frame: During procedure
Left atrial dwell time
The duration that the catheter stays in the left atrium
Time frame: During procedure
Total number of ablations
The total number of ablation discharges
Time frame: During procedure
Total ablation duration
The total ablation discharge time
Time frame: During procedure
Fluoroscopy time
Fluoroscopy time
Time frame: During procedure
Radiation dose
Radiation dose
Time frame: During procedure
Acute pulmonary vein isolation rate
Acute pulmonary vein isolation rate
Time frame: During procedure
Arterial PaCO₂ immediately before discontinuation of sedation/anesthesia
Arterial PaCO₂ immediately before discontinuation of sedation/anesthesia
Time frame: During procedure
Operative Sedation Assessment Scale
Please ask the patient to recall how much pain they felt during the surgery?(0-10, the higher the score, the more severe the pain)
Time frame: 12-24 hours postoperatively
Atrial fibrillation recurrence at 30 days post-procedure
Atrial fibrillation recurrence at 30 days post-procedure
Time frame: Day30
Atrial fibrillation recurrence at 90 days post-procedure
Atrial fibrillation recurrence at 90 days post-procedure
Time frame: Day90
Atrial fibrillation burden at 90 days post-procedure
Use 3 days of electrocardiogram patch monitoring to assess the burden of atrial fibrillation(Atrial fibrillation burden (%) = Total duration of atrial fibrillation ÷ Effective monitoring duration × 100%)
Time frame: Day90
Serious adverse events
SAE refers to adverse reactions that meet any of the following criteria: * Death or life-threatening * Resulting in severe and permanent disability * Requiring hospitalization or prolonging hospital stay * Causing congenital abnormalities or birth defects in offspring * A significant medical event determined by the researcher to cause major harm or injury to the subject, which may require drug treatment or surgical intervention to prevent the occurrence of other conditions as defined by SAE (such as death, permanent disability, hospitalization, etc.).
Time frame: Day0-90
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.